Precision Biosciences Inc
Precision Biosciences Inc (DTIL) Options Open Interest
DTIL options open interest is 1,110 contracts. The 2-week average daily volume is 21 contracts across the chain.
Read more
Monitoring DTIL open interest helps you see where real money is positioned on Precision Biosciences Inc's options and which strikes are attracting the most commitment from traders. Precision Biosciences Inc's open interest reflects the total number of outstanding contracts that have not been closed or exercised, making it a powerful gauge of liquidity, conviction, and potential support and resistance zones. Use our scanner to monitor DTIL options open interest in real time and find the strikes that matter.
Open interest is distinct from volume: volume counts how many contracts are traded in a session, while open interest counts how many remain open at the end of the day. Rising DTIL options open interest alongside rising volume suggests new positions are being built, while falling open interest signals positions are being closed. Heavy open interest at specific strikes often acts as a magnet near expiration and can hint at where dealers and large traders expect Precision Biosciences Inc to settle.
Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing and ex vivo allogeneic CAR T therapies in the United States. It offers ARCUS, a genome editing platform to cure genetic disorders. The company also provides Ex vivo Allogeneic CAR T Immunotherapy, a form of immunotherapy in which T cell, a specific type of immune cell is genetically engineered to recognize and kill cancer cells; PBCAR0191, which is in Phase 1/2a clinical trial in adult patients with R/R NHL or R/R B-cell precursor acute lymphoblastic leukemia, or B-ALL; PBCAR19B, an anti-CD19 CAR T candidate built on the stealth cell platform utilizing a single-step gene edit to minimize the risk of chromosome abnormalities; and PBCAR269A, an investigational allogeneic CAR T immunotherapy targeting BCMA for the treatment of R/R multiple myeloma.
The company has development and commercial license agreement with Les Laboratoires Servier to develop allogeneic chimeric antigen receptor T cell therapies for antigen targets, hematological cancer targets beyond CD19, and solid tumor targets; Tiziana Life Sciences to evaluate foralumab, a fully human anti-CD3 monoclonal antibody as a lymphodepleting agent for the potential treatment of cancers; and iECURE, Inc. to develop ARCUS-based gene editing therapies. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.
Pin risk into expiration, dealer positioning, liquidity checks for large orders — all of it starts with knowing where DTIL open interest is concentrated. Our scanner maps Precision Biosciences Inc's open interest across every strike and expiry, flags unusual buildups, and lets you drill into the contracts that institutional money is actually holding. Trade Precision Biosciences Inc's options open interest as the signal it is, not as an afterthought.
| 7.50 | — | 2.25 | 2.25 | 330% | +0.6458 | 44 |
| 2.50 | 2.00 | 6.70 | 4.35 | 41% | +1.0000 | 0 |
| 5.00 | 0.10 | 4.90 | 2.50 | 173% | +0.8531 | 0 |
| 10.00 | — | 4.00 | 4.00 | 689% | +0.7555 | 0 |
| 12.50 | — | 4.90 | 4.90 | 911% | +0.8221 | 0 |
| 7.50 | 0.40 | 4.90 | 2.65 | 347% | -0.3458 | 1 |
| 2.50 | — | 4.90 | 4.90 | 1,000% | -0.0456 | 0 |
| 5.00 | — | 4.90 | 4.90 | 1,000% | -0.0782 | 0 |
| 10.00 | 1.35 | 5.50 | 3.43 | 196% | -0.6573 | 0 |
| 12.50 | 3.40 | 8.00 | 5.70 | 216% | -0.7662 | 0 |
As of September 22, 2026
Follow the money
Track DTIL open interest across every strike and expiration, identify where conviction is building, and trade with the positioning data on your side.
Start your 14-day free trial→